keyword
MENU ▼
Read by QxMD icon Read
search

valganciclovir

keyword
https://www.readbyqxmd.com/read/27815572/phase-i-ii-study-of-lenalidomide-and-alemtuzumab-in-refractory-chronic-lymphocytic-leukemia-cll-effects-on-t-cells-and-immune-checkpoints
#1
Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Håkan Mellstedt, Anders Österborg, Jeanette Lundin
This phase I-II study explored safety, immunomodulatory and clinical effects of lenalidomide (weeks 1-16) and alemtuzumab (weeks 5-16) in 23 patients with refractory chronic lymphocytic leukemia. Most patients had Rai stage III/IV disease and were heavily pretreated (median 4 prior therapies), and 61% had del(17p)/del(11q). Eleven of 19 evaluable patients (58%) responded, with a median response duration of 12 months (1-29+); time to progression was short in non-responders. Lenalidomide had a narrow therapeutic dose range, 2...
November 4, 2016: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/27795766/-role-of-oral-antiviral-therapy-in-the-treatment-of-acute-retinal-necrosis
#2
Samia El Haouzi, Amina Jait, Omar Lezrek, Tachfouti Samira, Laghmari Amina, Ouafa Cherkaoui, Karman Abdellouahed, Rajae Daoudi
: Acute retinal necrosis syndrome (ARNS) is a rare but devastating uveitic syndrome with devastating visual outcome (visual prognosis ++). It should be diagnosed as early as possible because of its severity and its risk of bilateralization. This is a rare entity caused by the group of herpes viruses. In immunocompromised patients the complications of RNA syndrome often lead to loss of visual acuity. After the discovery of this disease using polymerase chain reaction (PCR) and immune load coefficient (ILC) usually by puncturing the cornea to evacuate the aqueous humour, the confirmation of this diagnosis allows for faster optimization of disease management decreasing the time required to confirm the diagnosis...
2016: Pan African Medical Journal
https://www.readbyqxmd.com/read/27790727/durable-remission-of-both-multicentric-castleman-s-disease-and-kaposi-s-sarcoma-with-valganciclovir-rituximab-and-liposomal-doxorubicin-in-an-hhv-8-positive-hiv-negative-patient
#3
C Murphy, E Hawkes, F Chionh, G Chong
WHAT IS KNOWN AND OBJECTIVE: Human herpesvirus-8 (HHV-8)-positive, HIV-negative multicentric Castleman's disease is a rare lymphoproliferative disorder with no standardized treatment. Concurrent Kaposi's sarcoma, another HHV-8-related disease, is uncommon in HIV-negative patients. The role of antiviral therapy and rituximab in HIV-negative patients is not well established. CASE DESCRIPTION: We report a case of a 5-year, durable remission of HHV-8-positive, HIV-negative comorbid multicentric Castleman's disease and Kaposi's sarcoma treated with long-term valganciclovir, following initial rituximab and liposomal doxorubicin...
October 28, 2016: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/27772620/cytomegalovirus-and-other-%C3%AE-herpesviruses
#4
Carlos A Q Santos
Cytomegalovirus (CMV), human herpes virus (HHV)-6, and HHV-7 are ubiquitous β-herpesviruses that can cause opportunistic infection and disease in kidney transplant recipients. Active CMV infection and disease are associated with acute allograft failure and death, and HHV-6 and HHV-7 replication are associated with CMV disease. CMV prevention strategies are used commonly after kidney transplantation, and include prophylaxis with antiviral medications and preemptive treatment upon the detection of asymptomatic viral replication in blood...
September 2016: Seminars in Nephrology
https://www.readbyqxmd.com/read/27760756/how-i-treat-resistant-cytomegalovirus-infection-in-hematopoietic-cell-transplantation-recipients
#5
Firas El Chaer, Dimpy P Shah, Roy F Chemaly
Cytomegalovirus (CMV) infection is a significant complication in hematopoietic cell transplantation (HCT) recipients. Four antiviral drugs are used for preventing or treating CMV: ganciclovir, valganciclovir, foscarnet, and cidofovir. With prolonged and repeated use of these drugs, CMV can become resistant to standard therapy, resulting in increased morbidity and mortality, especially in HCT recipients. Antiviral drug resistance should be suspected when CMV viremia (DNAemia or antigenemia) fails to improve or continue to increase after 2 weeks of appropriately dosed and delivered antiviral therapy...
October 19, 2016: Blood
https://www.readbyqxmd.com/read/27759493/experimental-and-computational-studies-on-the-effects-of-valganciclovir-as-an-antiviral-drug-on-calf-thymus-dna
#6
Nahid Shahabadi, Mehdi Pourfoulad, Neda Hosseinpour Moghadam
DNA-binding properties of an antiviral drug, valganciclovir (valcyte) was studied by using emission, absorption, circular dichroism, viscosity, differential pulse voltammetry, fluorescence techniques, and computational studies. The drug bound to calf thymus DNA (ct-DNA) in a groove-binding mode. The calculated binding constant of UV-vis, Ka, is comparable to groove-binding drugs. Competitive fluorimetric studies with Hoechst 33258 showed that valcyte could displace the DNA-bound Hoechst 33258. The drug could not displace intercalated methylene blue from DNA double helix...
October 19, 2016: Nucleosides, Nucleotides & Nucleic Acids
https://www.readbyqxmd.com/read/27753183/tolerability-of-up-to-200%C3%A2-days-of-prophylaxis-with-valganciclovir-oral-solution-and-or-film-coated-tablets-in-pediatric-kidney-transplant-recipients-at-risk-of-cytomegalovirus-disease
#7
G Varela-Fascinetto, C Benchimol, R Reyes-Acevedo, M Genevray, D Bradley, J Ives, H T Silva
This multicenter, open-label study evaluated the tolerability of extended prophylaxis with valganciclovir in pediatric kidney transplant recipients at risk of CMV disease. Fifty-six patients aged 4 months to 16 years received once-daily valganciclovir oral solution and/or tablets, dosed by BSA and renal function, for up to 200 days. The most common AEs on treatment were upper respiratory tract infection (33.9%), urinary tract infection (33.9%), diarrhea (32.1%), leukopenia (25.0%), neutropenia (23.2%), and headache (21...
October 17, 2016: Pediatric Transplantation
https://www.readbyqxmd.com/read/27704725/the-efficacy-of-valganciclovir-for-prevention-of-infections-with-cytomegalovirus-and-epstein-barr-virus-after-kidney-transplant-in-children
#8
Bernadette M Cameron, Sean E Kennedy, William D Rawlinson, Fiona E Mackie
This study evaluated the efficacy of prophylactic ValGCV in preventing CMV and EBV infections in a single-center pediatric kidney transplant population (2008-2014). Therapy duration was determined according to donor/recipient serostatus. EBV monitoring was performed using monthly plasma PCR for 18 months post-transplant and for CMV, monthly for 6 months after prophylaxis cessation. Data were collected on 35 children, median age 10.6 years. There were 15 (42.9%) and 11 (31.4%) recipients seronegative for CMV or EBV, respectively, who received a kidney from a seropositive donor...
October 4, 2016: Pediatric Transplantation
https://www.readbyqxmd.com/read/27673425/treatment-of-perinatal-viral-infections-to-improve-neurologic-outcomes
#9
REVIEW
William J Muller
Viral infections in the fetus or newborn often involve the central nervous system (CNS) and can lead to significant morbidity and mortality. Substantial progress has been made in identifying interventions decreasing adverse neurodevelopmental outcomes in this population. This review highlights progress in treatment of important viruses affecting the CNS in these susceptible hosts, focusing on herpes simplex virus (HSV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), and enteroviruses. The observation that high-dose acyclovir improves mortality in neonatal HSV disease culminated decades of antiviral research for this disease...
October 26, 2016: Pediatric Research
https://www.readbyqxmd.com/read/27661068/descemet-stripping-automated-endothelial-keratoplasty-outcomes-in-patients-with-cytomegalovirus-endotheliitis
#10
Ester Fernández López, Elsie Chan
PURPOSE: There is currently limited information regarding the outcomes of endothelial keratoplasty in eyes with cytomegalovirus (CMV) endotheliitis. We report the results of Descemet stripping automated endothelial keratoplasty (DSAEK) for endothelial failure secondary to CMV. METHODS: This is a retrospective review of 4 eyes of 4 patients with CMV endotheliitis and DSAEK. CMV was confirmed in each case by a positive aqueous tap on qualitative polymerase chain reaction...
September 21, 2016: Cornea
https://www.readbyqxmd.com/read/27640117/a-questionnaire-based-assessment-of-numbers-motivation-and-medical-care-of-uk-patients-undergoing-liver-transplant-abroad
#11
Ben Kerr Winter, Anand Odedra, Steve Green
BACKGROUND: Medical tourism, where patients travel abroad intentionally to access medical treatment, is a growing trend. Some of these patients travel to undergo organ transplantation. This study aims to quantify the number of UK patients who undergo liver transplantation abroad, assessing their motivations and management. METHODS: Questionnaires were sent to all seven UK liver transplant units enquiring about liver patients receiving transplant abroad. Included were questions on destination, motivation, and pre and post-transplant care...
September 14, 2016: Travel Medicine and Infectious Disease
https://www.readbyqxmd.com/read/27639246/multicenter-evaluation-of-efficacy-and-safety-of-low-dose-versus-high-dose-valganciclovir-for-prevention-of-cmv-disease-in-donor-and-recipient-positive-d-r-renal-transplant-recipients
#12
S Heldenbrand, C Li, R P Cross, K A DePiero, T B Dick, K Ferguson, M Kim, E Newkirk, J M Park, J Sudaria-Kerr, E M Tichy, K R Ueda, R Weng, J Wisniewski, S Gabardi
BACKGROUND: The cytomegalovirus (CMV) donor-positive/recipient-positive (D+/R+) population is the largest proportion of renal transplant recipients (RTR). Guidelines for prevention of CMV in the intermediate-risk D+/R+ population include prophylaxis with valganciclovir (VGCV) 900 mg/day for 3 months. This study is the first head-to-head analysis comparing the efficacy and safety CMV prophylaxis of VGCV 450 vs. 900 mg/day for 3-months in D+/R+ RTR. METHODS: A multicenter, retrospective analysis evaluated 478 adult RTR between 01/2008 and 10/2011...
September 17, 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27607910/update-on-treatment-of-cytomegalovirus-infection-in-pregnancy-and-of-the-newborn-with-congenital-cytomegalovirus
#13
William D Rawlinson, Stuart T Hamilton, Wendy J van Zuylen
PURPOSE OF REVIEW: The purpose of this review is to assess the recent studies of therapy of pregnant women and neonates, aimed at preventing the consequences of congenital cytomegalovirus (CMV) infection. RECENT FINDINGS: A recent randomized controlled trial of treatment of CMV during pregnancy with hyperimmune globulin did not show significant efficacy in prevention of foetal infection and morbidity, although there was a trend towards improvement with treatment...
December 2016: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/27583207/cytomegalic-hepatitis-in-a-patient-receiving-omalizumab
#14
R Gonçalves, C Valente, E Ferreira, J E Serra, J Saraiva da Cunha
Cytomegalovirus is a double stranded DNA virus that can be present in nearly all organs and body fluids. The primary infection is usually asymptomatic in the immunocompetent host and it is common among adolescents and young adults. The symptomatic form appears, in the majority of cases, as a mononucleosis syndrome with full recovery without specific treatment. We report a case of a 25 years old woman who presented with hepatitis due to CMV infection and history of omalizumab administration one month earlier...
2016: IDCases
https://www.readbyqxmd.com/read/27580058/pharmacokinetics-and-safety-of-valganciclovir-in-pediatric-heart-transplant-recipients-4-months-of-age-and-younger
#15
Denise Bradley, Sebastian Moreira, Vishak Subramoney, Clifford Chin, Jane Ives, Ka Wang
BACKGROUND: Valganciclovir (VGCV) effectively prevents cytomegalovirus disease in adult and pediatric solid organ transplant (SOT) recipients. A dosing algorithm for VGCV for pediatric patients, based on body surface area and renal function, provides a personalized dose using age-appropriate formulations. The suitability of this dosing algorithm has not been assessed specifically in infants and neonates 4 months of age and younger receiving a SOT. METHODS: This multicenter prospective study evaluated the pharmacokinetics (PK) and safety of VGCV oral solution in 17 heart transplant recipients 4 months of age and younger who received two doses of VGCV on consecutive days using the pediatric dosing algorithm...
August 30, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27569944/extended-low-dose-valganciclovir-is-effective-prophylaxis-against-cytomegalovirus-in-high-risk-kidney-transplant-recipients-with-near-complete-eradication-of-late-onset-disease
#16
S A Fayek, E Beshears, R Lieber, N Alvey, A Sauer, J Poirier, E F Hollinger, O K Olaitan, S Jensik, J Geyston, M M Brokhof, A C Hodowanec, M Hertl, D M Simon
BACKGROUND: Cytomegalovirus (CMV)-seronegative kidney transplant (KTx) recipients of organs from CMV-seropositive donors (D+/R-) are at increased risk for CMV infection. Despite valganciclovir (VGCV) prophylaxis (900 mg daily for 200 days), late-onset CMV (LO-CMV) occurs at excessive rates. VGCV-associated cost and toxicities remain problematic. METHODS: We retrospectively evaluated 50 D+/R- adult KTx recipients from August 2008 to August 2014 who received low-dose VGCV (450 mg daily) prophylaxis for an extended duration...
July 2016: Transplantation Proceedings
https://www.readbyqxmd.com/read/27545492/the-role-of-antiviral-prophylaxis-for-the-prevention-of-epstein-barr-virus-associated-posttransplant-lymphoproliferative-disease-in-solid-organ-transplant-recipients-a-systematic-review
#17
M A AlDabbagh, M R Gitman, D Kumar, A Humar, C Rotstein, S Husain
The role of antiviral prophylaxis for the prevention of posttransplant lymphoproliferative disease (PTLD) remains controversial for solid organ transplantation (SOT) recipients who are seronegative for Epstein-Barr virus (EBV) but who received organs from seropositive donors. We performed a systematic review and meta-analysis to address this issue. Two independent assessors extracted data from studies after determining patient eligibility and completing quality assessments. Overall, 31 studies were identified and included in the quantitative synthesis...
August 22, 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/27530217/bottom-up-meets-top-down-complementary-physiologically-based-pharmacokinetic-and-population-pharmacokinetic-modeling-for-regulatory-approval-of-a-dosing-algorithm-of-valganciclovir-in-very-young-children
#18
K Jorga, C Chavanne, N Frey, T Lave, V Lukacova, N Parrott, R Peck, B Reigner
Population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) models are frequently used to support pediatric drug development. Both methods have strengths and limitations and we used them complementarily to support the regulatory approval of a dosing algorithm for valganciclovir (VGCV) in children <4 months old. An existing pediatric PBPK model was extended to neonates and showed that potential physiological differences compared with older children are minor. The PopPK model was used to simulate ganciclovir (GCV) exposures in children with population typical combinations of body size and renal function and to assess the effectiveness of an alternative dosing algorithm suggested by the US Food and Drug Administration...
August 17, 2016: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27515131/the-chemical-class-of-quinazoline-compounds-provides-a-core-structure-for-the-design-of-anticytomegaloviral-kinase-inhibitors
#19
C Hutterer, S Hamilton, M Steingruber, I Zeitträger, H Bahsi, N Thuma, Z Naing, Z Örfi, L Örfi, E Socher, H Sticht, W Rawlinson, S Chou, V J Haupt, M Marschall
HCMV is a member of the family Herpesviridae and represents a worldwide distributed pathogen with seropositivity rates in the adult population ranging between 40% and 90%. Notably, HCMV infection is a serious, sometimes life-threatening medical problem for newborns and immunosuppressed individuals, including transplant recipients and patients under antitumoral chemotherapy. Current standard therapy with valganciclovir has the disadvantage of inducing drug-resistant virus mutants and toxicity-related side effects...
October 2016: Antiviral Research
https://www.readbyqxmd.com/read/27506260/cytomegalovirus-treatment-strategy-after-a-liver-transplant-preemptive-therapy-or-prophylaxis-for-cytomegalovirus-seropositive-donor-and-recipient
#20
Kirsten Lindner, Christoph Anthoni, Susanne Beckebaum, Norbert Senninger, Jens Peter Hölzen, Heiner Wolters
OBJECTIVES: Cytomegalovirus infections cause the most frequent infection after solid-organ transplant. While Cytomegalovirus prophylaxis is established in high-risk patients (donor+/ recipient-), data on Cytomegalovirus prophylaxis in other serostatus constellation are rare. The aim of this study was to evaluate the influence of Cytomegalovirus treatment strategy after a liver transplant (preemptive therapy vs general prophylaxis) in the largest group of patients: Cytomegalovirus seropositive donor and recipient...
August 2016: Experimental and Clinical Transplantation
keyword
keyword
38260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"